SPRINT, Royal Columbian Hospital Medicine rounds, Nov 10, 2015
•
3 gefällt mir•1,650 views
We discussed the recently published SPRINT trial, which compared a BP systolic target of <140><120 mm Hg in patients with hypertension.
Empfohlen
Weitere ähnliche Inhalte
Was ist angesagt?
Was ist angesagt? (20)
Ähnlich wie SPRINT, Royal Columbian Hospital Medicine rounds, Nov 10, 2015
Ähnlich wie SPRINT, Royal Columbian Hospital Medicine rounds, Nov 10, 2015 (20)
Kürzlich hochgeladen
Kürzlich hochgeladen (20)
SPRINT, Royal Columbian Hospital Medicine rounds, Nov 10, 2015
- 1. SPRINT FROM @NEJM BP TARGET < 120 VS < 140 MM HG Daniel Schwartz, MD Nov 13, 2015
- 2. BP TARGETS THEY KEEP CHANGING
- 4. BACKGROUND WHY TREAT HYPERTENSION ▸ Treatment to reduce elevated blood pressure can lead to reduction in ▸ coronary artery disease (CAD) ▸ congestive heart failure ▸ stroke ▸ chronic kidney disease irrespective of age, sex, race or ethnic background and HTN severity
- 5. BACKGROUND OBSERVATIONAL ▸ Observational studies ▸ linear relationship between blood pressure and cardiovascular risk down to 115/75 mm Hg ▸ J-curve - is it confounded?
- 6. BACKGROUND CURRENT CHEP GUIDELINES: BP TARGETS ▸ <130/80 mm Hg: Diabetes ▸ <150 mm Hg systolic: >80 years ▸ <140/90: All else
- 7. BACKGROUND IN DIABETES ▸ Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial ▸ Systolic BP < 120 mm Hg vs <140 mm Hg ▸ no difference in cardiovascular events in DM2
- 8. TRIAL
- 9. METHODOLOGY
- 10. TRIAL TRIAL DESIGN ▸ randomized, controlled, open-label trial ▸ multicenter ▸ randomization stratified by site ▸ blinded outcome adjudicators (patients/researchers not blinded) ▸ primary analysis compared time to 1st occurrence of primary outcome event with intention-to-treat ▸ independent data and safety monitoring board monitored unblinded trial results and safety events
- 11. TRIAL FUNDING ▸ NIH ▸ no industry funds
- 12. TRIAL INCLUSION ▸ age >= 50 years ▸ Systolic blood pressure ▸ 130 – 180 mm Hg on 0 or 1 medication ▸ 130 – 170 mm Hg on up to 2 medications ▸ 130 – 160 mm Hg on up to 3 medications ▸ 130 – 150 mm Hg on up to 4 medications ▸ increased risk of cardiovascular events ▸ clinical or subclinical cardiovascular disease other than stroke ▸ CKD excluding polycystic kidney disease (eGFR 20-60) ▸ 10-year risk of cardiovascular disease >= 15% (Framingham) ▸ age >= 75 years
- 13. TRIAL EXCLUSION ▸ Diabetes ▸ Hx of stroke ▸ An indication for a specific BP lowering medication ▸ Secondary hypertension ▸ Orthostatic BP < 110 ▸ PKD, GN needing immunosuppression ▸ >1gm/day proteinuria ▸ EF < 35% ▸ Recent heart failure < 6 months, cardiac event < 3 months
- 14. TRIAL INTERVENTION ▸ BP target <140 vs 120 ▸ Treatment algorithm ▸ lifestyle ▸ drugs
- 15. TRIAL PRIMARY OUTCOME ▸ Composite ▸ myocardial infarction ▸ acute coronary syndrome ▸ stroke ▸ acute decompensated heart failure ▸ death from cardiovascular causes
- 16. RESULTS
- 17. RESULTS STOPPED EARLY ▸ 9361 patients enrolled ▸ Aug 20, 2015 - terminated early due to improved outcome with intensive target
- 20. RESULTS BLOOD PRESSURES ▸ Baseline ▸ 139.7/78.2 mm Hg (intensive) ▸ 139.7/78.0 mm Hg (standard) ▸ 1 year ▸ 121.4/68.7 mm Hg (intensive) with 2.8 meds ▸ 136.2/76.3 mm Hg (standard) with 1.8 meds
- 21. RESULTS RESULTS ▸ Intensive-treatment ▸ 25% RRR of major cardiovascular events (95% CI, 11 to 36) ▸ 27% RRR of death (95% CI, 10 to 40)
- 23. RESULTS NNT TO PREVENT A PRIMARY OUTCOME EVENT: 61 DEATH FROM ANY CAUSE: 90 DEATH FROM CARDIOVASCULAR CAUSES: 172 OVER MEDIAN 3.26 YEARS
- 24. RESULTS SERIOUS ADVERSE EVENTS ▸ Intensive arm: 4.7% vs ▸ Standard arm: 2.5% serious adverse events (HR, 1.88; P<0.001)
- 26. METHODS METHODOLOGIC ISSUES? ▸ Stopping early ▸ can overestimate benefit in small trials ▸ unlikely with > 500 primary outcome events ▸ Lack of blinding (BP can be measured) ▸ mitigated by structured assessment of outcomes and adverse events
- 27. METHODS GENERALIZABILITY ▸ Cannot apply to those with ▸ Diabetes ▸ History of Stroke ▸ Institutionalized Elderly ▸ Advanced/highly proteinuric CKD
- 28. METHODS RISK VS BENEFIT ▸ Do benefits outweigh risks?
- 29. CURRENT GUIDELINES … REQUIRE REVISION. Vlado Perkovic, for the NEJM
- 30. TAKE AWAY REAL WORLD ▸ BP goal of 140/90 mm Hg ▸ US: 33-50% not at target ▸ Many developing countries: >90% not at target
- 31. 16.8 MILLION US ADULTS MEET INCLUSION CRITERIA J Am Coll Cardiol. 2015;():. doi:10.1016/j.jacc.2015.10.037
- 32. TAKE AWAY NEPHROLOGY PRACTICE ▸ 28% had GFR 20-60 ml/min ▸ Excluded ▸ GFR < 20 ▸ Proteinuria > 1gm ▸ Excluded highest risk for progression to ESRD
- 33. TAKE AWAY SIGNIFICANT EFFORT ▸ in SPRINT ▸ initial combination therapy ▸ monthly visits until BP at target
- 36. CLINICAL TRIALS ARE DIFFERENT FROM REAL LIFE
- 37. TAKE AWAY REAL WORLD ▸ Adoption of lower BP targets would mean ▸ more cautious titration of medications ▸ more combination treatment ▸ more care watching for adverse effects ▸ more frequent visits ▸ addressing lifestyle issues (physical activity, salt intake, obesity, sleep apnea, and alcohol use) ▸ population-level initiatives (eg sodium in food)
- 38. TAKE AWAY MORE HELP ▸ People ▸ Nurse practitioners ▸ Physician assistants, ▸ Pharmacists ▸ Others? ▸ Treatment algorithms ▸ Algorithmic monitoring/EHRs?